Aradigm Corporation
Aradigm Receives FDA Clearance for Phase IIb Clinical Trial of Inhaled Liposomal Ciprofloxacin to Treat Bronchiectasis
Published in Medical Letter on the CDC and FDA, August 9th, 2009
Aradigm Corporation (OTCBB:ARDM) (the "Company") announced it received clearance from the U.S. Food and Drug Administration (FDA) for its inhaled liposomal ciprofloxacin Investigational New Drug (IND) application. The initial clinical protocol under this IND is an international, randomized, double-blind, placebo-controlled Phase IIb study designed to evaluate the Company's inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis (BE). This orphan drug condition is a chronic severe respiratory disease and there is currently no drug specifically approved for its treatment in the U.S.
"We are very pleased that the FDA accepted our data package to...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Johns Hopkins Medical Institutions
Hepatitis C infection: treatment options equally effective, likelihood of success known early on - University of Rochester Medical Center
Breast cancer drug shows promise against serious infections - Celgene Corporation
Celgene Reports Record Second Quarter 2009 Operating and Financial Results - Chronic Obstructive Pulmonary Disease
Nycomed Announces FDA Filing for Daxas(R) in COPD - Depression
New findings reported from University of Sussex describe advances in depression - Food and Drug Law Institute
FDLI Publishes New FDA Directory With Obama Appointees - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
